Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials

[41] Kim Y(2008)Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes Diabetes Obes Metab. 10 959-1419

[42] Rascati KL(2008)Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes Curr Med Res Opin 24 537-483

[43] Wu D(2006)Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone Diabetes Care. 29 2638-1474

[44] Li L(2011)Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naı¨ve patients with type 2 diabetes Int J Clin Pract. 65 930-333

[45] Liu C(2012)Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study Diabetes Care. 35 252-60

[46] McKeage K(2007)Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial Diabetes Obes Metab. 9 194-745

[47] Kavosi Z(2011)Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, doubleblind, non-inferiority trial Diabetes Obes Metab. 13 160-undefined

[48] Khorrami MS(2010)Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial Lancet 376 431-undefined

[49] Keshavarz K(2010)Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes Diabet Med. 27 1409-undefined

[50] Jafari A(2012)2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, noninferiority trial Lancet (North American Edition) 380 475-undefined

[41] Kim Y(2008)Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes Diabetes Obes Metab. 10 959-1419

[42] Rascati KL(2008)Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes Curr Med Res Opin 24 537-483

[43] Wu D(2006)Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone Diabetes Care. 29 2638-1474

[44] Li L(2011)Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naı¨ve patients with type 2 diabetes Int J Clin Pract. 65 930-333

[45] Liu C(2012)Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study Diabetes Care. 35 252-60

[46] McKeage K(2007)Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial Diabetes Obes Metab. 9 194-745

[47] Kavosi Z(2011)Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, doubleblind, non-inferiority trial Diabetes Obes Metab. 13 160-undefined

[48] Khorrami MS(2010)Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial Lancet 376 431-undefined

[49] Keshavarz K(2010)Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes Diabet Med. 27 1409-undefined

[50] Jafari A(2012)2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, noninferiority trial Lancet (North American Edition) 380 475-undefined